Premium
Pneumocystis jirovecii pneumonia after rituximab therapy for antibody‐mediated rejection in a renal transplant recipient
Author(s) -
Kumar D.,
Gourishankar S.,
Mueller T.,
Cockfield S.,
Weinkauf J.,
Vethanayagam D.,
Humar A.
Publication year - 2009
Publication title -
transplant infectious disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.69
H-Index - 67
eISSN - 1399-3062
pISSN - 1398-2273
DOI - 10.1111/j.1399-3062.2008.00345.x
Subject(s) - medicine , rituximab , pneumocystis jirovecii , pneumonia , immunology , renal transplant , antibody , transplantation , kidney transplantation , intensive care medicine
We report the case of a 54‐year‐old woman who underwent living‐related renal transplantation for end‐stage renal disease from IgA nephropathy. She was subsequently diagnosed with antibody‐mediated rejection (AMR) and received rituximab, a potent B‐cell suppressive agent. After therapy with rituximab, she developed Pneumocystis jirovecii pneumonia (PJP) requiring hospitalization. We discuss the increasing literature for the use of rituximab for AMR and the need for PJP prophylaxis in this setting.